Talphera Inc.
Cerrado
0.75 -2.6
Resumen
Variación precio
24h
Mínimo
0.73
Máximo
0.78
Ingresos | 1.2M -2.6M |
|---|---|
Margen de beneficios | -443,600 |
Empleados | 12 |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +306.41% upside |
Próximas Ganancias | 13 ago 2026 |
|---|
Capitalización Mercado | 35M |
|---|---|
Apertura anterior | 3.35 |
Cierre anterior | 0.75 |
Talphera Inc. Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Talphera Inc. previsión
Precio Objetivo
By TipRanks
306.41% repunte
Estimación a 12 Meses
Media 3.17 USD 306.41%
Máximo 3.5 USD
Mínimo 3 USD
De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Talphera Inc. Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Beneficio antes de impuestos
Ventas
Gasto por intereses de deuda
Beneficio operativo
$
Acerca de Talphera Inc.
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. It is also developing LTX-608, an anti-inflammatory and antiviral potential for the treatment of multiple conditions, including disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis; Fedsyra, a pre-filled ephedrine syringe; and PFS-02, a pre-filled phenylephrine syringe. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
